Anti-CD13, Recombinant [22A5]
Invented at Queen Mary University of London
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153258 |
| Applications | FACS IHC IP |
| Antigen/Gene or Protein Targets | Aminopeptidase N (CD13) |
| Synonyms | Alanyl Aminopeptidase; Membrane; Microsomal Aminopeptidase; Aminopeptidase M; Myeloid Plasma Membrane Glycoprotein CD13; GP150; CD13; PEPN |
| Reactivity | Human |
| Relevance | Aminopeptidase N (CD13) is a cell-surface metalloprotease involved in the metabolism of regulatory peptides. 22A5 may be useful for the diagnosis and immunophenotyping of leukaemia. |
| Host | Mouse |
| Immunogen | A cell suspension containing osteoclasts from osteoclastomas. |
| Subclass | IgG2a kappa |
| Formulation | PBS |
| Concentration | 1mgml-1 |
| Positive Control | Cells of myelomonocytic lineage |
| Research Area | Cancer, Immunology, Metabolism |
| Notes |
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. Six products based on this clone: - Anti-CD13 [22A5], Mouse IgG2a, Kappa - Anti-CD13 [22A5], Mouse IgG2a, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors - Anti-CD13 [22A5], Rabbit IgG, Kappa - Anti-CD13 [22A5], Human IgG4-S228P, Kappa - Anti-CD13 [22A5], Human IgG1, Kappa - Anti-CD13 [22A5], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors |
References: 1 entry
Original hybridoma first published in: Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038.
Add a reference
References: 1 entry
Original hybridoma first published in: Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038.
Add a reference
